Navigation Links
EUCODIS Bioscience Appoints Thomas Fischer as New CEO

VIENNA, Austria, December 7 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry, announced today that it has appointed Mr Thomas Fischer, currently CFO, as new CEO of the Company. Going forward, EUCODIS Bioscience' sole focus will be to provide high-performance enzymes to customers, capitalizing on the Company's experience in commercial enzyme development and on its proven technology of "in vivo recombination".

In line with this move EUCODIS Bioscience will spin out its French research subsidiary in a management buy-in lead by Rudy Pandjaitan, PhD, previously CEO of EUCODIS Bioscience.

Dr. Pandjaitan will acquire a majority stake in the new entity. Under his leadership the new entity will develop next-generation applications of "in vivo recombination". EUCODIS Bioscience will retain a strategic share in its former subsidiary.

"White Biotechnology, or enzyme-based products and manufacturing, is a 100 billion Euro market, and EUCODIS Bioscience is well positioned to exploit the huge commercial potential of this business", said Thomas Fischer, CEO of EUCODIS Bioscience. "It was under Rudy's leadership that the Company has developed into this position, and we are pleased that he will continue to actively support EUCODIS Bioscience in the area of business development as a consultant."

"EUCODIS Bioscience' technology is a powerful and proven tool for the creation of novel enzymes", said Dr. Pandjaitan. "Even more fascinating, in vivo recombination may also be used in synthetic biology, generating DNA strands of more than 10,000 base pairs on a routine basis. It is our vision that in vivo recombination will enable the creation of novel pathways and even whole genomes, providing a key technology for the 'cellular factory' of the future."

"In vivo recombination" is EUCODIS Bioscience' proprietary, patent-protected technology for the development of industrial enzymes with novel properties.

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, customizes, manufactures, and markets industrial enzymes.

EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with a subsidiary in Germany.

    For more information, please visit

    Company contact EUCODIS Bioscience:
    Thomas Fischer, MBA
    EUCODIS Bioscience
    Campus Vienna Biocenter II
    Viehmarktgasse 2 a/ 2 OG
    A-1030 Vienna

    Media contact EUCODIS Bioscience:
    Frank Butschbacher
    Investor Relations & Communications


Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus
2. EUCODIS Bioscience Launches Lipase Portfolio
3. EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries
4. EUCODIS Bioscience Signs Research Agreement With Genencor
5. EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone
6. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
7. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
8. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
9. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
11. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
Post Your Comments:
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces a presentation ... San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness Center ... the needs of consumers who are incorporating medical marijuana into their wellness and ... , As operators of two successful Valley dispensaries, The Giving Tree’s two founders, ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech Venture ... sector at their fourth annual Conference where founders, investors, innovative practitioners and collaborators ... ELEVATE pitch competition showcasing early stage digital health and med tech companies. , ...
Breaking Biology Technology:
(Date:8/23/2017)...  The general public,s help is being enlisted in what,s thought to ... and on the human body –and are believed to affect health.  ... The Microbiome Immunity Project is the largest ... the gut. The project's goal is to help advance scientific knowledge of ... ...
(Date:6/23/2017)... N.Y. , June 23, 2017  IBM (NYSE: ... dairy research, today announced a new collaboration using next-generation ... chances that the global milk supply is impacted by ... Cornell University has become the newest academic institution to ... a food safety initiative that includes IBM Research, Mars, ...
(Date:5/16/2017)... , May 16, 2017   Bridge Patient ... organizations, and MD EMR Systems , an ... partner for GE, have established a partnership to ... product and the GE Centricity™ products, including Centricity ... These new integrations will allow ...
Breaking Biology News(10 mins):